FLT3 and acute myeloid leukemia: The median OS and DFS was statistically similar for AML patients with or without FLT3 mutations (median OS: 12 months vs. 17 months, P= 0.2247; median DFS: 18 months vs. 12 months, P= 0.8653, respectively; Table 3, Figure 8).